Effects of the Oral Administration of Mosapride Citrate on Capsule Endoscopy Completion Rate

Abstract

Background/AimsIn capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion.MethodsIn a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time.ResultsThe univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT).ConclusionsOral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.

Modified bowel preparation regimen for use in second‐generation colon capsule endoscopy in patients with ulcerative colitis

“…The current and previous study protocols are shown in Tables and previous data suggested that prokinetic drugs reduce the gastric transit and small bowel transit times, leading to an improvement of the completion rate . Therefore, two prokinetic drugs, mosapride citrate and metoclopramide were used in the current protocol.…”

Applicability of second‐generation colon capsule endoscope to ulcerative colitis: A clinical feasibility study

“…Mosapride citrate (mosapride), a selective 5‐hydroxytryptamine‐4 receptor agonist, increases gastrointestinal motility . Our recent data suggest that oral administration of mosapride reduces the gastric transit time and small bowel transit time during small bowel capsule procedures. A few clinical studies have shown that mosapride in combination with polyethylene glycol solution (PEG) may enhance bowel cleansing and improve acceptability and tolerability for patients .…”

Feasibility of a novel low-volume and sodium phosphate-free bowel preparation regimen for colon capsule endoscopy

“…Mosapride is an emerging prokinetic agent, working as a 5-hydroxytryptamine receptor 4 agonist and accelerating both gastric emptying and peristalsis of the small intestine (28). Wei et al (29) and Ida et al (30) recommended that patients received 10 mg mosapride citrate 30-60 min prior to capsule ingestion. However, the dosage and administration time of mosapride remain to be evaluated.…”